By Sandy Smith
When discussions turn to future therapies for those with bleeding disorders, it’s pretty obvious that gene therapy is at the top of the list. It dominated much of Candid Conversations: What Do Docs Think about Future Therapies?
Chris Bombardier, MS, executive director of the international nonprofit Save One Life, moderated the Friday session. Panelists included Glenn Pierce, MD, PhD, vice president of medical with the World Federation of Hemophilia; Mark Reding, MD, adult hematologist and director, Center for Bleeding and Clotting Disorders, University of Minnesota Medical School; and Vilmarie Rodriguez, MD, pediatric hematologist and thrombosis and anticoagulation program director at Nationwide Children's Hospital and The Ohio State University.
Story continues here...
By Vicky Uhland
“What would you like to see this community look like in 2030 if time, effort and, importantly, money was not an issue?"
NHF asked this question of its members in 2020, and NHF President and CEO Leonard Valentino, MD, restated it during the Friday session Getting to 2030 Blue Sky Vision: A Community Conversation.
“The answer I got was a Yogiism: It’s tough to make predictions, especially about the future,” Valentino said with a laugh.
NHF Daily is brought to you by our following partners: